Kura Oncology Future Growth

Future criteria checks 2/6

Kura Oncology is forecast to grow earnings and revenue by 26% and 62.1% per annum respectively while EPS is expected to grow by 33.2% per annum.

Key information

26.0%

Earnings growth rate

33.2%

EPS growth rate

Biotechs earnings growth	24.1%
Revenue growth rate	62.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	03 May 2024

Recent future growth updates

Recent updates

Kura Oncology: Ziftomenib's Path To AML Market Widens

Jan 31

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Jan 25

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Aug 14

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Apr 04

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Jan 31

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Oct 10

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

Jul 13

What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Dec 14

Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks

Dec 10

Kura Oncology (KURA) Presents At ASH Virtual Investor Event

Dec 08

Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

Dec 07

Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow

Nov 17

Earnings and Revenue Growth Forecasts

NasdaqGS:KURA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	109	-191	-209	N/A	7
12/31/2025	12	-220	-196	N/A	9
12/31/2024	N/A	-201	-196	N/A	10
3/31/2024	N/A	-168	N/A	N/A	N/A
12/31/2023	N/A	-153	-125	-125	N/A
9/30/2023	N/A	-143	-117	-117	N/A
6/30/2023	N/A	-140	-110	-109	N/A
3/31/2023	N/A	-137	-114	-114	N/A
12/31/2022	N/A	-136	-111	-110	N/A
9/30/2022	N/A	-135	-108	-107	N/A
6/30/2022	N/A	-133	-112	-110	N/A
3/31/2022	N/A	-132	-109	-108	N/A
12/31/2021	N/A	-130	-106	-105	N/A
9/30/2021	N/A	-124	-101	-99	N/A
6/30/2021	N/A	-114	-93	-92	N/A
3/31/2021	N/A	-101	-80	-79	N/A
12/31/2020	N/A	-90	-72	-70	N/A
9/30/2020	N/A	-81	-67	-65	N/A
6/30/2020	N/A	-74	-62	-61	N/A
3/31/2020	N/A	-68	-61	-60	N/A
12/31/2019	N/A	-63	-55	-55	N/A
9/30/2019	N/A	-61	-51	-51	N/A
6/30/2019	N/A	-60	-52	-52	N/A
3/31/2019	N/A	-60	-50	-50	N/A
12/31/2018	N/A	-60	-49	-49	N/A
9/30/2018	N/A	-55	-46	-46	N/A
6/30/2018	N/A	-49	-39	-39	N/A
3/31/2018	N/A	-43	-33	-33	N/A
12/31/2017	N/A	-35	N/A	-28	N/A
9/30/2017	N/A	-32	N/A	-28	N/A
6/30/2017	N/A	-30	N/A	-27	N/A
3/31/2017	N/A	-28	N/A	-27	N/A
12/31/2016	N/A	-28	N/A	-25	N/A
9/30/2016	N/A	-27	N/A	-24	N/A
6/30/2016	N/A	-26	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-21	N/A
12/31/2015	N/A	-23	N/A	-18	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KURA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KURA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KURA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KURA's revenue (62.1% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: KURA's revenue (62.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KURA's Return on Equity is forecast to be high in 3 years time

Kura Oncology Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 10% to US$28.46

Price target decreased to US$32.67

Price target decreased to US$38.43

Price target decreased to US$41.63

Price target raised to US$33.50

Price target raised to US$28.25

Recent updates

Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology: Ziftomenib's Path To AML Market Widens

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Chairman notifies of intention to sell stock

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

New minor risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Price target decreased by 10% to US$28.46

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold US$61k worth of stock

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib

Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company,

Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$32.67

Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Price target decreased to US$38.43

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Insider notifies of intention to sell stock

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Independent Director Robert Hoffman has left the company

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

Kura Oncology Investor Presentation - Slideshow

Price target decreased to US$41.63

Chief Operating Officer exercised options and sold US$63k worth of stock

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

New 90-day low: US$29.15

Kura Oncology, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day low: US$29.73

Chief Operating Officer exercised options and sold US$199k worth of stock

What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

New 90-day high: US$40.67

Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks

Kura Oncology (KURA) Presents At ASH Virtual Investor Event

Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 At American Society of Hematology Annual Meeting

Chairman exercised options to buy US$436k worth of stock.

Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow